-
Determination of endometrial cancer molecular subtypes using a whole exome-sequencing based single-method approach
-
Biomedical Curator (m/f/d)
We are seeking for our headquarters in Heidelberg a highly motivated Biomedical Curator (m/f/d) We are seeking a highly motivated individual with a strong scientific background to aid us in further developing our ground-breaking clinical databases and knowledge resources. Your tasks: Your skills and qualifications: We offer: Molecular Health believes in the principles of equal…
-
Linux System Engineer (DevOps) (m/f/d)
We are seeking for our headquarters in Heidelberg a highly motivated Linux System Engineer (DevOps) (m/f/d) You are a problem solver who loves to collaborate to find the best possible technical solutions and you love Linux. We have very complex products and you have the ambition to understand them better than we do. Your tasks:…
-
Junior Quality Manager (m/f/d)
We are seeking for our headquarters in Heidelberg a highly motivated Junior Quality Manager (m/f/d) In this position, you will work closely with all departments as a member of the Quality Management team and report to the VP Corporate Quality Management. Your tasks: Your skills and qualifications: We offer: Molecular Health believes in the principles…
-
Integrated DNA Technologies and Molecular Health Ink Commercial Partnership
CORALVILLE, Iowa and HEIDELBERG, Germany (May 15, 2024)—Genomics solutions provider Integrated DNA Technologies (IDT) and Bio-IT company Molecular Health have entered into a global multi-year agreement, starting in the U.S., to integrate their next generation sequencing (NGS) capabilities. The partnership pairs IDT’s Archer NGS research assay platform with Molecular Health’s variant annotation and reporting software…
-
A multigene mutation classification of 468 colorectal cancers reveals a prognostic role for APC
-
Bioinformatory-assisted analysis of next-generation sequencing data for precision medicine in pancreatic cancer
-
Consolidated BRCA1/2 Variant Interpretation by MH BRCA Correlates with Predicted PARP Inhibitor Efficacy Association by MH Guide
-
Whole Exome Analysis to Select Targeted Therapies for Patients with Metastatic Breast Cancer – A Feasibility Study
-
Rewiring Drug Research and Development through Human Data-Driven Discovery (HD3)
-
Determination of the Cancer Genome Atlas (TCGA) Endometrial Cancer Molecular Subtypes Using the Variant Interpretation and Clinical Decision Support Software MH Guide
-
Whole patient knowledge modeling of COVID-19 symptomatology reveals common molecular mechanisms
-
Advancing drug safety science by integrating molecular knowledge with post‐marketing adverse event reports
-
Evaluation of the TruSight Tumor 170 Assay and Its Value in Clinical Diagnostics
-
Application of a patient-centered reverse translational systems-based approach to understand mechanisms of an adverse drug reaction of immune checkpoint inhibitors
-
The COVID-19 explorer – An integrated, whole patient knowledge model of COVID-19 disease
-
Target adverse event profiles for predictive safety in the postmarket setting
-
A case study of a patient-centered reverse translational systems-based approach to understand adverse event profiles in drug development
